122 related articles for article (PubMed ID: 3460626)
1. Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements.
Preisler HD; Priore R; Azarnia N; Barcos M; Raza A; Rakowski I; Vogler R; Winton EL; Browman G; Goldberg J
Br J Haematol; 1986 Aug; 63(4):625-36. PubMed ID: 3460626
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.
Preisler HD; Azarnia N; Raza A; Grunwald H; Vogler R; Browman G; Goldberg J; Chervenick P; Miller K; Brennan J
Br J Haematol; 1984 Mar; 56(3):399-407. PubMed ID: 6582925
[TBL] [Abstract][Full Text] [Related]
3. Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
Preisler HD; Epstein J; Barcos M; Priore R; Raza A; Browman GP; Vogler R; Winton E; Grunwald H; Rai K
Br J Haematol; 1984 Sep; 58(1):19-32. PubMed ID: 6466567
[TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
[TBL] [Abstract][Full Text] [Related]
5. Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy.
Preisler H; Barcos M; Reese P; Priore RL; Pothier L
Leuk Res; 1983; 7(1):67-75. PubMed ID: 6572773
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the drug sensitivity of acute nonlymphocytic leukaemia using the in vitro clonogenic assay.
Preisler HD; Azarnia N
Br J Haematol; 1984 Dec; 58(4):633-40. PubMed ID: 6518136
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of acute megakaryoblastic leukaemia.
Ninomiya H; Nakazawa M; Shibuya A; Aoki Y; Nagasawa T; Abe T
Scand J Haematol; 1986 Feb; 36(2):147-53. PubMed ID: 3458290
[TBL] [Abstract][Full Text] [Related]
8. Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
Sampi K; Sakurai M; Kaneko Y; Hattori M
Oncology; 1986; 43(1):18-22. PubMed ID: 3455751
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.
Preisler HD; Raza A; Barcos M; Azarnia N; Larson R; Walker I; Browman M; Grunwald H; D'Arrigo P; Doeblin T
J Clin Oncol; 1987 Jan; 5(1):75-82. PubMed ID: 3806162
[TBL] [Abstract][Full Text] [Related]
10. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
Cassileth PA; Begg CB; Silber R; Spiers A; Burkart PT; Scharfman W; Knospe WH; Bennett JM; Mazza JJ; Oken MM
Cancer Treat Rep; 1987 Feb; 71(2):137-40. PubMed ID: 3802110
[TBL] [Abstract][Full Text] [Related]
11. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
Sampi K; Honda T; Hayashi Y; Hattori M
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
[TBL] [Abstract][Full Text] [Related]
12. Daunorubicin versus aclarubicin in combination with cytarabine and thioguanine in elderly patients with acute nonlymphocytic leukemia, a preliminary report.
Björkholm M; Killander A
Eur J Haematol Suppl; 1987; 47():49-54. PubMed ID: 3471525
[No Abstract] [Full Text] [Related]
13. Treatment of acute non-lymphocytic leukemia in Saitama Cancer Center.
Sampi K; Sakurai M; Kaneko Y; Hattori M
Anticancer Res; 1985; 5(3):293-6. PubMed ID: 4015043
[TBL] [Abstract][Full Text] [Related]
14. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.
Stone RM; Maguire M; Goldberg MA; Antin JH; Rosenthal DS; Mayer RJ
Blood; 1988 Mar; 71(3):690-6. PubMed ID: 3422828
[TBL] [Abstract][Full Text] [Related]
15. Treatment of erythroleukemia with anthracycline antibiotics and cytosine arabinoside.
Tamura K; Preisler HD
Cancer; 1983 May; 51(10):1795-9. PubMed ID: 6572541
[TBL] [Abstract][Full Text] [Related]
16. Reinduction chemotherapy for acute nonlymphocytic leukemia.
Letendre L; Kiely JM; Hoagland HC
Mayo Clin Proc; 1984 Sep; 59(9):618-21. PubMed ID: 6381915
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure.
Preisler HD; Reese PA; Marinello MJ; Pothier L
Br J Haematol; 1983 Mar; 53(3):459-66. PubMed ID: 6824587
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with acute nonlymphocytic leukemia in relapse: a Leukemia Intergroup study.
Goldberg J; Grunwald H; Vogler WR; Winton E; Browman G; Walker I; Benger A; Miller KB; Rai K; Gottlieb AJ
Am J Hematol; 1985 Jun; 19(2):167-76. PubMed ID: 3890525
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
Preisler HD; Rustum YM; Azarnia N; Priore R
Cancer Chemother Pharmacol; 1987; 19(1):69-74. PubMed ID: 3815728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
